Sex: Female
Histology: Adenocarcinoma
Key Mutations: EGFR L858R, TP53 R248Q, MET Amplified,
ERBB2 Amplified
Molecular Characteristics: MSK-IMPACT
Matched Normal: Yes
Treatment: erlotinib
Site: Lung
Paired: No
Comments: erlotinib resistant
Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes. For more information, please contact [email protected].
Stage of Development
Ready to use